SAM
KYMR icon

Shell Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Shell Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$95K Sell
1,670
-2,147
-56% -$96.8K 0.01% 658
2025
Q2 		$167K Sell
3,817
-109
-3% -$3.75K 0.01% 838
2025
Q1 		$107K Sell
3,926
-170
-4% -$6.2K 0.01% 996
2024
Q4 		$165K Hold
4,096
– – 0.01% 900
2024
Q3 		$194K Buy
+4,096
New +$181K 0.01% 847
2024
Q1 		$129K Sell
4,330
-437
-9% -$15.6K 0.01% 952
2023
Q4 		$121K Buy
+4,767
New +$85.3K 0.01% 1007

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Shell Asset Management's KYMR Position: Q3 2025 in Review

Shell Asset Management reduced its Kymera Therapeutics (KYMR) stake by 56% in Q3 2025, selling an estimated $96.8K and leaving 1,670 shares worth $95K. The position accounts for 0.01% of the portfolio, ranked #658.

Shell Asset Management first reported a position in KYMR in Q4 2023 and has held it in 7 quarters since. The position peaked at $194K in Q3 2024. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Shell Asset Management held 1,670 shares of Kymera Therapeutics worth $95K as of Q3 2025.
  • Shell Asset Management sold 2,147 Kymera Therapeutics shares in Q3 2025, an estimated $96.8K.
  • Kymera Therapeutics made up 0.01% of Shell Asset Management's portfolio in Q3 2025, its #658 holding.
  • Shell Asset Management first reported a position in Kymera Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • Shell Asset Management's Kymera Therapeutics position peaked at $194K in Q3 2024.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.